Rate My Professor Luke Gray Whiley

Dr. Luke Gray Whiley is a Senior Lecturer in Phenomics, Healthy Ageing and Dementia at the Health Futures Institute, Murdoch University. He earned his PhD from King's College London and subsequently held postdoctoral positions at the UK Dementia Research Institute and Imperial College London. Following these roles, he took up a lectureship at Murdoch University, advancing to his current senior lectureship. His research specializes in metabolic phenotyping to elucidate mechanisms underlying neurodegenerative diseases, including the metabolic impacts of ABCA7 genetic polymorphisms in sporadic Alzheimer's disease, inhibition of β-amyloid aggregation by natural compounds, lipid remodelling in Parkinson's disease, and characterization of intrinsic skin metabolic phenotypes.

Dr. Whiley is a Dementia Australia and Royce Simmons Foundation Mid-Career Research Fellow, supporting his project on advancing understanding of genetic risk factors in Alzheimer's disease. In 2021, he was recognized as a rising star in metabolomics and proteomics on the American Chemical Society's 40 under 40 list. He has received funding from the Future Health Research and Innovation Fund for developing a molecular atlas of skin metabolism. Notable publications include '3-Deoxyanthocyanidins inhibit β-amyloid aggregation, toxicity, and seeded aggregation: evidence from MC-65 cells and molecular dynamics simulations' (2026), 'Inhibition Effect and Molecular Mechanisms of Quercetin on Amyloid-β Oligomerization' (2023, ACS Omega), and contributions to serum lipidomics studies revealing class-specific alterations in Parkinson's disease neurons. As a member of the Executive Committee of the Australian and New Zealand Society for Mass Spectrometry, he contributes to advancing mass spectrometry applications in research. Dr. Whiley actively engages the public as project officer for Perth's Pint of Science Festival, through appearances on ABC Perth Radio and the Naked Scientists podcast, and via social media campaigns for dementia charities, amplifying the impact of his work in healthy ageing and dementia research.